1. Home
  2. SCLX vs TLSA Comparison

SCLX vs TLSA Comparison

Compare SCLX & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • TLSA
  • Stock Information
  • Founded
  • SCLX 2011
  • TLSA 2013
  • Country
  • SCLX United States
  • TLSA United Kingdom
  • Employees
  • SCLX N/A
  • TLSA N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • TLSA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SCLX Health Care
  • TLSA Health Care
  • Exchange
  • SCLX Nasdaq
  • TLSA Nasdaq
  • Market Cap
  • SCLX 81.7M
  • TLSA 87.8M
  • IPO Year
  • SCLX N/A
  • TLSA 2000
  • Fundamental
  • Price
  • SCLX $0.40
  • TLSA $0.74
  • Analyst Decision
  • SCLX Strong Buy
  • TLSA
  • Analyst Count
  • SCLX 3
  • TLSA 0
  • Target Price
  • SCLX $11.33
  • TLSA N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • TLSA 380.8K
  • Earning Date
  • SCLX 01-07-2025
  • TLSA 12-31-2024
  • Dividend Yield
  • SCLX N/A
  • TLSA N/A
  • EPS Growth
  • SCLX N/A
  • TLSA N/A
  • EPS
  • SCLX N/A
  • TLSA N/A
  • Revenue
  • SCLX $50,833,000.00
  • TLSA N/A
  • Revenue This Year
  • SCLX $32.77
  • TLSA N/A
  • Revenue Next Year
  • SCLX $50.71
  • TLSA N/A
  • P/E Ratio
  • SCLX N/A
  • TLSA N/A
  • Revenue Growth
  • SCLX 9.41
  • TLSA N/A
  • 52 Week Low
  • SCLX $0.40
  • TLSA $0.41
  • 52 Week High
  • SCLX $2.63
  • TLSA $1.74
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 29.75
  • TLSA 29.00
  • Support Level
  • SCLX $0.43
  • TLSA $0.73
  • Resistance Level
  • SCLX $0.51
  • TLSA $1.07
  • Average True Range (ATR)
  • SCLX 0.06
  • TLSA 0.09
  • MACD
  • SCLX -0.01
  • TLSA -0.03
  • Stochastic Oscillator
  • SCLX 7.30
  • TLSA 5.00

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Share on Social Networks: